Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo revestimiento para stents liberadores de medicamentos empleados para tratar enfermedades de la uretra

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOSG20161003001
Publicado:
09/11/2016
Caducidad:
09/11/2017
Resumen:
Un grupo de instituciones de salud pública de Singapur ha desarrollado un nuevo revestimiento para stents liberadores de medicamentos empleados para tratar enfermedades de la uretra. Esta tecnología tiene como objetivo mejorar los tratamientos actuales de enfermedades de la uretra en urología. El transporte de medicamentos a través del tejido urotelial mejora porque el hidrogel se hincha y entra en contacto con la pared ureteral. Se buscan pymes, muntinacionales, universidades y centros de I+D interesados en establecer acuerdos de licencia o joint venture.

Details

Tittle:
A novel coating for drug delivery stents used to treat ureteric conditions
Summary:
A Singapore group of public healthcare institutions has developed a novel coating for drug delivery stents used to treat ureteric conditions. This technology aims to improve on current treatment options for ureteric diseases in urology practice.

The group is seeking commercialization partnerships with SMEs of any sizes, MNEs, universities or R-Y-D institutions with interest to explore a license agreement or joint venture for this coating technology.
Description:
This technology developed by the Singapore group of public healthcare institutions aims to solve the problem of ureteric diseases such as strictures and carcinoma (especially in the upper tract where treatment is difficult).

Current methods comprising endoscopic full-thickness incision of the ureteric wall and placement of an indwelling stent for up to 6 weeks are not always successful, and are associated with recurrent obstruction and hence may require repeated interventions. Current stents serve only as passive internal scaffolds and do not address any pathology conditions. e.g. fibrosis, infection, tumours.

The devised technology relates to a swellable drug eluting ureteric stent that delivers the drug into the proximate diseased ureteric tissues. Drug transport through the urothelial tissue is enhanced as the hydrogel swells and contacts with the ureteric wall. It has been reported that postoperative administration of adjuvant topical drugs can reduce recurrence of the ureteric disease. However, the challenge remains to achieve efficacious drug concentration in the target tissue (Nicholas A Williams et al, 2016). There is currently no drug-eluting ureteric stent or localized drug therapy for urology on the market.

The technology comprises a first layer of anti-proliferative drug incorporated into a polymer, and then a second layer of hydrogel which can swell as it absorbs urine. The swollen hydrogel makes contacts with the ureteric lining and enhances the localized delivery of the drug into the lowly permeable targeted ureteric tissues. In-vitro drug release studies have demonstrated that the drug, with tunable dosage, can be released over a sustained period of 1 month or more (common indwelling stenting duration) and the coated section can swell up to approximately 4.5 - 5 mm in diameter (common ureteric diameter in adults). The drugs eluted are able to inhibit bladder stroma fibroblasts in vitro.

A working prototype has been made and in vivo results have demonstrated that the coated stent can be inserted and removed by clinicians. Pharmacokinetic and histology studies are currently ongoing. Ureteric stent placement is not a new technique and is very commonly practiced in urology as an adjunct to endoscopic surgery, and treatment can be easily terminated by simply removing the stent.

The Singapore healthcare organisation is seeking to commercialize the technology to global industry players such as SMEs of any sizes, MNEs, universities or R-Y-D institutions that are interested to explore the following:

- License agreement
- Joint venture agreement
Advantages and Innovations:
This novel swellable hydrogel coating technology provides the following innovations and advantages:

1) It is clinically relevant to healthcare (urology) practice for treatment of ureteric diseases.

2) The technology is compatible for use with any commercially available ureteric stent.

3) This novel swellable hydrogel coating technology is clinically relevant to healthcare (urology) practice for treatment of ureteric diseases.

4) The technology is compatible for use with any commercially available ureteric stent. The novel stent coating aims to address particularly the problems of benign strictures and malignant disease (carcinoma) of the ureter.

The value proposition lies in its applicability to existing urological practice (stent insertion) while providing a unique solution by delivering drugs directly into the ureteric wall in a sustained fashion. Treatment is easily terminated by removal of the stent which is also currently practiced. Urologists will find this technology easy to incorporate into their practice to address particularly the problems of benign strictures and malignant disease (carcinoma) of the ureter.
Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The types of partners sought include:
- >500
- >500 MNE
- 251-500
- SME <10
- SME 11-50
- SME 51-250
- University
- Inventor
- R-Y-D Institution

The types of partnerships considered include:
- Joint venture agreement
- License agreement

The role of the partner would be to either commercialise the technology to bring to market or to further develop this technology to meet the demand-driven needs of the addressable market.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001024 Biomateriales médicos
06001017 Cirugía
06001013 Tecnología médica / ingeniería biomédica